​

Denali Therapeutics (DNLI) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

DNLI Stock Forecast

Denali Therapeutics (DNLI) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $38.50, with a high of $45.00 and a low of $32.00. This represents a 202.20% increase from the last price of $12.74.

$10 $17 $24 $31 $38 $45 High: $45 Avg: $38.5 Low: $32 Last Closed Price: $12.74

DNLI Stock Rating

Denali Therapeutics stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (93.75%), 1 Hold (6.25%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 1 15 Strong Sell Sell Hold Buy Strong Buy

DNLI Price Target Upside V Benchmarks

TypeNameUpside
StockDenali Therapeutics202.20%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--7
Avg Price Target--$34.57
Last Closing Price$12.74$12.74$12.74
Upside/Downside--171.35%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 254141--19
Mar, 254141--19
Feb, 254131--18
Jan, 254131--18
Dec, 244113--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 07, 2025Thomas ShraderBTIG$32.00$21.1851.09%151.18%
Nov 01, 2024Michael YeeJefferies$45.00$27.0566.36%253.22%
Oct 14, 2024Thomas ShraderBTIG$35.00$28.0025.00%174.73%
Sep 04, 2024Tazeen AhmadBank of America Securities$29.00$25.1215.45%127.63%
Sep 03, 2024Marank MamtaniB.Riley Financial$33.00$25.1231.37%159.03%
Sep 03, 2024Salveen RichterGoldman Sachs$46.00$25.1283.12%261.07%
Sep 03, 2024Paul MattelsStifel Nicolaus$22.00$25.12-12.42%72.68%
Aug 05, 2021Salveen RichterGoldman Sachs$112.00$52.93111.60%779.12%
May 18, 2021Esther RajaveluUBS$70.00$55.5126.10%449.45%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 03, 2025OppenheimerOutperformOutperformhold
Jan 07, 2025JefferiesBuyBuyhold
Jan 07, 2025BTIGBuyBuyhold
Jan 07, 2025H.C. WainwrightBuyBuyhold
Jan 03, 2025William BlairOutperforminitialise
Nov 01, 2024JefferiesBuyBuyhold
Oct 14, 2024BTIGBuyBuyhold
Oct 11, 2024Cowen & Co.BuyBuyhold
Oct 07, 2024Cantor FitzgeraldNeutraldowngrade
Sep 03, 2024Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.65$-2.39$-2.60$-1.06$-2.57----
Avg Forecast$-1.54$-2.26$-2.62$-0.99$-2.78$-3.02$-2.49$-1.54$-0.51
High Forecast$-0.47$-0.70$0.13$-0.90$-2.58$-2.55$-0.55$1.81$0.13
Low Forecast$-2.15$-3.16$-4.64$-1.17$-2.92$-3.52$-3.48$-3.19$-1.07
Surprise %-142.21%5.75%-0.76%7.07%-7.55%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$335.66M$48.66M$108.46M$330.53M-----
Avg Forecast$92.10M$75.99M$109.51M$337.70M$9.31M$42.00M$191.62M$421.67M$657.93M
High Forecast$120.12M$99.11M$174.56M$359.24M$10.67M$78.12M$194.99M$435.68M$1.22B
Low Forecast$43.10M$35.56M$20.95M$329.35M$8.54M$1.39M$188.26M$407.65M$21.74M
Surprise %264.46%-35.96%-0.96%-2.12%-----

Net Income Forecast

$-5B $6B $17B $28B $39B $50B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$71.14M$-290.58M$-325.99M$-145.22M$-422.77M----
Avg Forecast$41.42B$-178.35M$-242.60M$-145.22M$-378.17M$-416.75M$-443.44M$-226.87M$-69.54M
High Forecast$49.80B$-142.68M$-194.08M$-116.18M$-355.10M$-350.51M$-75.73M$249.01M$17.88M
Low Forecast$33.04B$-214.02M$-291.12M$-174.27M$-401.24M$-482.99M$-477.91M$-437.81M$-147.31M
Surprise %-99.83%62.93%34.37%-11.79%----

DNLI Forecast FAQ

Is Denali Therapeutics stock a buy?

Denali Therapeutics stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Denali Therapeutics is a favorable investment for most analysts.

What is Denali Therapeutics's price target?

Denali Therapeutics's price target, set by 16 Wall Street analysts, averages $38.5 over the next 12 months. The price target range spans from $32 at the low end to $45 at the high end, suggesting a potential 202.20% change from the previous closing price of $12.74.

How does Denali Therapeutics stock forecast compare to its benchmarks?

Denali Therapeutics's stock forecast shows a 202.20% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Denali Therapeutics over the past three months?

  • April 2025: 21.05% Strong Buy, 73.68% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 21.05% Strong Buy, 73.68% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 22.22% Strong Buy, 72.22% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.

What is Denali Therapeutics’s EPS forecast?

Denali Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.02, marking a 17.51% increase from the reported $-2.57 in 2024. Estimates for the following years are $-2.49 in 2026, $-1.54 in 2027, and $-0.51 in 2028.

What is Denali Therapeutics’s revenue forecast?

Denali Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $42M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $191.62M, followed by $421.67M for 2027, and $657.93M for 2028.

What is Denali Therapeutics’s net income forecast?

Denali Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-417M, representing a -1.42% decrease from the reported $-423M in 2024. Projections indicate $-443M in 2026, $-227M in 2027, and $-69.544M in 2028.